This is a 6-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 4 to 12 years old. The study is double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge. At the end of the 6-week double-blind period, patients can receive 6 weeks of olanzapine as part of the study.

Ages Eligible for Study:  4 Years   -   12 Years,  Genders Eligible for Study:  Both

Criteria

1. Diagnosis of Autistic Disorder (DSM-IV Criteria).

2. Includes both males and females.

3. Aged 4 to 12 years inclusive.

4. Physically Healthy.